eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

2/2014
vol. 39
 
Share:
Share:
more
 
 
abstract:

Clinical immunology
Recombinant human interleukin receptor antagonist influences serum chemokines in patients with rheumatoid arthritis

Jun Bao
,
Wei Liu
,
Yi-Xiao Bao

(Centr Eur J Immunol 2014; 39 (2): 170–173)
Online publish date: 2014/06/27
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Objective: To investigate the serum expressions of chemokines CCL2 and CCL3 in patients with rheumatoid arthritis (RA) who were treated with recombinant human interleukin 1 (IL-1) receptor antagonist (IL-1Ra).

Material and methods: Serum CCL2 and CCL3 were determined using an enzyme-linked immunosorbent assay in 54 active RA patients before and after treatment with IL-1Ra or a placebo, as well as 36 healthy controls.

Results: Compared with the healthy controls, all the 54 RA patients exhibited higher serum CCL2 and CCL3 before and after treatment (p < 0.05). However, patients who had a good response to IL-1Ra treatment had significantly lower mean changes in the serum CCL2 and CCL3 levels from baseline to the last injection than IL-1Ra non-responders (p < 0.01).

Conclusions: CCL2 and CCL3 may be useful efficacy markers of IL-1Ra treatment.
keywords:

arthritis, rheumatoid, chemokines, interleukin-1 receptor antagonist protein, drug therapy

FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe